​​The effort to require the Bureau of Land Management to implement a humane management strategy for America's wild horses with the immunocontraception, porcine zona pellucida (PZP), advanced through a FY21 U.S. House spending bill.  

Rep. Steve Cohen (D-TN) offered an amendment to the “State, Foreign Operations, Agriculture, Rural Development, Interior, Environment, Military Construction, and Veterans Affairs Appropriations Act”, which would mandate that at least $11M of the Bureau of Land Management’s FY21 wild horse and burro budget be allocated to administering PZP to mustangs on the range.

​Cosponsors of Cohen's amendment:
U.S. Representatives; Dina Titus (D-NM), Raul Grijalva (D-AZ), Joe Neguse (D-CO), Brian Fitzpatrick (R-PA), David Schweikert (R-AZ), David Price (D-NC), Peter King (R-NY), Deb Haaland (D-NM), John Katko (R-NY), Jan Schakowsky (D-IL), and Ben McAdams (D-UT).

Opposition:
By a vast majority, the U.S. House passed the amendment, but it did meet with one outspoken voice of opposition: Rep. Chris Stewart (R-UT). Stewart, who is a leading architect of the misguided and reckless, “Path Forward, 10 Years to AML agenda” for wild horses, decried the amendment. He stated on the U.S. House Floor, "While I appreciate the gentleman's concern for wild horses, it will end up hurting more than it helps." Stewart went on to say, “The amendment seeks to push PZP contraceptive. The only problem with that is it doesn't work.” 

​​​It’s extremely troubling that Rep. Stewart attempted to sabotage the amendment, especially as his 10 Years to AML agenda partners include the Humane Society of the United States (HSUS), American Society for the Prevention of Cruelty to Animals (ASPCA), and Return to Freedom (RTF). All three of these organizations support the use of PZP. In fact, HSUS holds the registrant for PZP under the name “ZonaStat-H” for use on wild horses and burros, ASPCA has provided financial support for PZP research and development, and RTF successfully utilizes PZP on the wild horses residing at their sanctuary. 

The next hurdle for the $11M mandate on PZP use will be in the U.S. Senate's FY 2021 spending bill that will be drafted and voted on in the next few months. 

​Two top horses, including an Arkansas Derby winner, were found to have a numbing agent in their systems. The Arkansas Racing Commission suspended the Hall of Fame trainer Bob Baffert for 15 days on Wednesday and vacated the victories of two of his horses after they tested positive for a banned substance.

​One of the horses, Charlatan, won a division of the Arkansas Derby on May 2. The colt’s owners will forfeit the $300,000 in prize money for finishing first. The owner of the other horse, a filly named Gamine, must forfeit a $36,000 first-place check won in an allowance race earlier that day. The suspension will run from Aug. 1 to 15.

On June 20, Gamine won the Acorn Stakes at Belmont Park in New York by nearly 19 lengths in a stakes-record time of 1 minute 32.55 seconds, a performance that inspired talk of the filly taking on males in the Kentucky Derby, which is scheduled for Sept. 5.

Baffert is America’s pre-eminent active trainer. He has won the Kentucky Derby five times. In 2015, he trained American Pharoah, the first horse to win the Triple Crown since Affirmed in 1978. Baffert won his second Triple Crown in 2018 with the colt Justify.

Lidocaine can be used legitimately for suturing wounds or as a diagnostic tool to determine if horses are sound enough to compete. The drug may also be present in ointments or creams used on cuts or abrasions. It is regulated because of its potential to mask lameness in an unsound horse.

In a hearing, Baffert and his representatives argued that the horses were accidentally exposed to the lidocaine by an assistant trainer, Jimmy Barnes, who had applied a medicinal patch to his own back. Barnes had broken his pelvis, and the brand of patch he used, Salonpas, contains small amounts of Lidocaine. The drug was transferred from his hands through the application of a tongue tie, they said.

A lawyer for Baffert, W. Craig Robertson, said the trainer was disappointed in the ruling and planned to appeal. In a statement, he said, “This is a case of innocent exposure and not intentional administration.”

Four days after Charlatan’s runaway victory in the Arkansas Derby, the colt’s stallion rights were sold for an undisclosed sum to Hill ‘n’ Dale Farms. The colt missed the Belmont Stakes with an ankle injury, and Baffert has said he will miss the Kentucky Derby, as well. Charlatan may be able to come back in time for the Preakness on Oct. 3.

Baffert-trained Justify failed a drug test after winning the Santa Anita Derby, nearly a month before the 2018 Kentucky Derby. Justify wound up winning the Derby, the Preakness and the Belmont that year for the Triple Crown. The rule on the books when Justify failed the test required that the horse be disqualified, forfeiting both his prize money from the Santa Anita Derby and his entry into the Kentucky Derby.

California racing officials investigated the failed test for four months, allowing Justify to keep competing long enough to win the Triple Crown. In August, after Justify’s breeding rights had been sold for $60 million, the California Horse Racing Board — whose chairman at the time, Chuck Winner, had employed Baffert to train his horses — disposed of the inquiry in a rare closed-door session.

The board ruled that Justify’s positive test for the banned drug scopolamine had been the result of “environmental contamination,” not intentional doping. Baffert has denied any wrongdoing, but the quantity of the drug found in Justify suggested that it was present not because of contamination in his feed or his bedding but rather because of an effort to enhance performance, according to Dr. Rick Sams, who ran the drug lab for the Kentucky Horse Racing Commission from 2011 to 2018.

Mick Ruis, the owner of the second-place horse in the Santa Anita Derby, is in litigation with California officials to have his colt Bolt d’Oro declared the winner and awarded the $600,000 first-place check.

​Source: New York Times